NCT06212479 An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.
| NCT ID | NCT06212479 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hercules |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100,000 participants |
| Start Date | 2024-05-17 |
| Primary Completion | 2034-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100,000 participants in total. It began in 2024-05-17 with a primary completion date of 2034-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, single-arm, observational study capturing data from whole-body magnetic resonance imagining (WB-MRI) from up to 100,000 male and female subjects 18 years of age or older recruited at multiple clinical sites within the United States. Study subjects must meet a set of inclusion and exclusion criteria. Potential subjects arriving at the study sites will be evaluated for enrollment. It is the Principal Investigator's (PI) responsibility to enroll only subjects who satisfy the inclusion/exclusion criteria. Recruitment can occur by subject presentation at the sites for elective standard screening, word-of-mouth, flyers, healthcare professional (HCP) referrals, advertisement online, or any other means, subject to approval by the associated institutional review board (IRB) or ethics committee (EC) when applicable.
Eligibility Criteria
Inclusion Criteria: * Each subject MUST: * Be\>=18 years of age at the time of enrollment. * Be able to read and understand provided procedural information for the study; * Be able and willing to follow all study procedures including proper breathing and body movement minimization while within the WB-MRI system; * Be willing and able to provide required clinical, demographic, medical history, and concomitant medications information; * Be able to provide financial payment in advance for reimbursement of the cost of the WBMRI acquisition procedure and interpretation; * Complete all required consent procedures. Exclusion Criteria: * Harbor within their bodies contraindicated medical devices including, but not limited to, implanted pacemakers, intracranial aneurysm clips, cochlear implants, drug infusion pumps, neurostimulators, bone growth stimulators, certain intrauterine contraceptive devices, non- MRI safe metals, etc.; * Self-certify that they are pregnant; * Be seeking to undergo WB-MRI as a subject in this study in lieu of other covered dedicated diagnostic imaging evaluations when such covered procedures represent more appropriate or standard-of-care procedures by context-specific clinical indication; * Be an employee of the study site or the sponsor; * Have a medical condition or serious intercurrent illness, or other circumstance that, in the Investigator's judgment, could jeopardize the candidate's safety as a study subject, or that could interfere with study objectives.
Contact & Investigator
Perry Kaneriya, MD, MBA
PRINCIPAL INVESTIGATOR
Hercules
Frequently Asked Questions
Who can join the NCT06212479 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06212479 currently recruiting?
Yes, NCT06212479 is actively recruiting participants. Contact the research team at kayla.macleod@herculesstudy.org for enrollment information.
Where is the NCT06212479 trial being conducted?
This trial is being conducted at Watertown, United States.
Who is sponsoring the NCT06212479 clinical trial?
NCT06212479 is sponsored by Hercules. The principal investigator is Perry Kaneriya, MD, MBA at Hercules. The trial plans to enroll 100,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.